Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 172

Results For "GE"

7096 News Found

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
News | April 07, 2025

Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis

Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers


Delhi becomes 35th state/UT to implement AB PM-JAY
Policy | April 07, 2025

Delhi becomes 35th state/UT to implement AB PM-JAY

Nadda noted that on the basis of economic caste census, 50 crore people were brought under this scheme


Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio
Digitisation | April 07, 2025

Siemens acquires Dotmatics for $5.1 billion to strengthen Life Sciences portfolio

Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries


Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal
News | April 07, 2025

Alife expands personal care portfolio with Gondhoraj & Neem soap in West Bengal

The unique soap-fusion of Gondhoraj lime and neem provides a refreshing skin-friendly experience


Fluor to provide EPCM services for pharmaceutical facility in Indiana
News | April 07, 2025

Fluor to provide EPCM services for pharmaceutical facility in Indiana

This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202


Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US
News | April 07, 2025

Sumitomo Chemical establishes a CRO for Oligonucleotide CDMO business in US

Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013


AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer
Drug Approval | April 04, 2025

AstraZeneca’s Imfinzi-based perioperative regimen approved in EU for resectable non-small cell lung cancer

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone


Lupin acquires UK-based Renascience Pharma for £12.3 million
News | April 04, 2025

Lupin acquires UK-based Renascience Pharma for £12.3 million

The portfolio includes branded injectable cephalosporines for infectious diseases


Gland Pharma receives approval for Acetaminophen Injection
Drug Approval | April 04, 2025

Gland Pharma receives approval for Acetaminophen Injection

The company expects to launch this product through its marketing partner in the near future